Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - cabergoline -

Canada - English - Health Canada

apotex inc - cabergoline - tablet - 0.5mg - cabergoline 0.5mg - ergot-derivative dopamine receptor agonists

United States - English - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - cabergoline (unii: ll60k9j05t) (cabergoline - unii:ll60k9j05t) - cabergoline 0.5 mg - cabergoline tablets are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas. cabergoline tablets are contraindicated in patients with: - uncontrolled hypertension or known hypersensitivity to ergot derivatives. - history of cardiac valvular disorders, as suggested by anatomical evidence of valvulopathy of any valve, determined by pre-treatment evaluation including echocardiographic demonstration of valve leaflet thickening, valve restriction, or mixed valve restriction-stenosis (see warnings ). - history of pulmonary, pericardial, or retroperitoneal fibrotic disorders (see warnings ).

United States - English - NLM (National Library of Medicine)

greenstone llc - cabergoline (unii: ll60k9j05t) (cabergoline - unii:ll60k9j05t) - cabergoline 0.5 mg - cabergoline tablets are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas. cabergoline tablets are contraindicated in patients with

United States - English - NLM (National Library of Medicine)

par pharmaceutical, inc. - cabergoline (unii: ll60k9j05t) (cabergoline - unii:ll60k9j05t) - cabergoline 0.5 mg - cabergoline tablets are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas. cabergoline tablets are contraindicated in patients with: - uncontrolled hypertension or known hypersensitivity to ergot derivatives. - history of cardiac valvular disorders, as suggested by anatomical evidence of valvulopathy of any valve, determined by pre-treatment evaluation including echocardiographic demonstration of valve leaflet thickening, valve restriction, or mixed valve restriction-stenosis (see warnings). - history of pulmonary, pericardial, or retroperitoneal fibrotic disorders (see warnings).

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - cabergoline (unii: ll60k9j05t) (cabergoline - unii:ll60k9j05t) - cabergoline tablets are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas. cabergoline tablets are contraindicated in patients with: - uncontrolled hypertension or known hypersensitivity to ergot derivatives. - history of cardiac valvular disorders, as suggested by anatomical evidence of valvulopathy of any valve, determined by pre-treatment evaluation including echocardiographic demonstration of valve leaflet thickening, valve restriction, or mixed valve restriction-stenosis (see warnings) - history of pulmonary, pericardial, or retroperitoneal fibrotic disorders. (see warnings).

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - cabergoline 0.5mg - tablet - 0.5 mg - active: cabergoline 0.5mg excipient: lactose leucine - prevention of the onset of lactation in the puerperium only for clearly defined medical reasons: arrow - cabergoline is indicated for the inhibition of physiological lactation soon after delivery. 1. after parturition, when breast feeding is contraindicated due to medical reasons related to the mother or the new-born. 2. after stillbirth or abortion. treatment of hyperprolactinaemic disorders: cabergoline is indicated for the treatment of dysfunctions associated with hyperprolactinaemia, including amenorrhoea, oligomenorrhoea, anovulation and galactorrhoea. cabergoline is indicated in patients with prolactin-secreting pituitary adenomas (micro- and macroprolactinomas), idiopathic hyperprolactinaemia, or empty sella syndrome with associated hyperprolactinaemia, which represent the basic underlying pathologies contributing to the above clinical manifestations.

Ireland - English - HPRA (Health Products Regulatory Authority)

renata pharmaceuticals (ireland) limited - cabergoline - tablet - cabergoline

Ireland - English - HPRA (Health Products Regulatory Authority)

renata pharmaceuticals (ireland) limited - cabergoline - tablet - cabergoline

Malta - English - Medicines Authority

teva pharma b.v. (mijdrecht) industrieweg 23, p.o. box 217, 3640 ae mijdrecht, netherlands - cabergoline - tablet - cabergoline 0.5 mg - other gynecologicals